- Home
- COCH vs HOTH Comparison
COCH vs HOTH Comparison
Compare COCH & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | HOTH |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 18.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | COCH | HOTH |
|---|---|---|
| Price | $0.84 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.50 | $4.50 |
| AVG Volume (30 Days) | ★ 541.8K | 276.6K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,000.00 | N/A |
| Revenue This Year | $3.66 | N/A |
| Revenue Next Year | $31.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.66 |
| 52 Week High | $2.32 | $3.80 |
Technical Indicators
Market Signals| Indicator | COCH | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 44.22 |
| Support Level | $0.66 | $1.14 |
| Resistance Level | $0.87 | $1.24 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 86.84 | 65.29 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).